tirzepatide vision loss Comparative ocular outcomes of versus other anti-obesity medications in people with obesity Scientists Explain 'Ozempic Blindness,' Link

In the STEP 2 trial, patients with type 2 diabetes who took semaglutide 2.4 mg lost nearly 9.6% of their body weight over 68 weeks, compared with approximately 3% on placebo

That does not mean every meal has to be huge or complicated

Post-marketing surveillance has reinforced that gastrointestinal adverse effectsparticularly nausea, vomiting, and diarrhoearemain the most common tolerability issues, typically occurring during dose escalation and often diminishing over time

The study reports that markers such as high cholesterol and elevated blood pressure tend to worsen again after medication use ends

Think youre in the clear